DISCLOSURES: The authors report no conflicts of interest.
1542-4863/asset/CAAC_left.gif?v=1&s=b30825cac69353e6291703284644f96de5014146)
1542-4863/asset/olbannerright.gif?v=1&s=c4e79cd950d71afe81f443027d81136e7d370bd2)
Review Article
You have free access to this content
Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma†
Article first published online: 15 OCT 2012
DOI: 10.3322/caac.21161
Copyright © 2012 American Cancer Society, Inc.
Additional Information
How to Cite
Maluccio, M. and Covey, A. (2012), Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA: A Cancer Journal for Clinicians, 62: 394–399. doi: 10.3322/caac.21161
- †
Publication History
- Issue published online: 19 NOV 2012
- Article first published online: 15 OCT 2012
References
- 1, , , , , . Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
- 2, , . Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
- 3, , , . Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin. 2012; 62: 118-128.
- 4. Hepatocellular carcinoma. J Hepatol. 2000; 32( suppl 1): 225-237.
- 5, , , et al. Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort [published online ahead of print May 23, 2012]. Int J Cancer. doi: 10.1002/ijc.27645.
- 6, ; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53: 1020-1022.
- 7, , , et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw. 2009; 7: 350-391.
- 8European Association for Study of Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012; 48: 599-641.
- 9, , , et al. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enchanced MR imaging. Radiology. 2011; 261: 834.
- 10. Diagnostic imaging of hepatocellular carcinoma: recent progress. Oncology. 2011; 81( suppl 1): 73-85.
- 11A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 1998; 28: 751-755.
- 12, , . Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999; 19: 329-338.
- 13, , , et al. V-CLIP: integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials. Cancer. 2011; 117: 2478-2488.
- 14, , , et al. I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IFG-1 into CLIP score. Oncology. 2011; 80: 373-381.
- 15, , , et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334: 693-699.
- 16, , , , , . Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl. 2002; 8: 765-774.
- 17, , , et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg. 2007; 246: 502-509; discussion 509-511.
- 18, . Current approach to down-staging of hepatocellular carcinoma prior to liver transplantation. Curr Opin Organ Transplant. 2008; 13: 234-240.
- 19, . An overview of evidence-based management of hepatocellular carcinoma: a meta-analysis. J Cancer Res Ther. 2011; 7: 463-475.
- 20, , . Systematic review of actual 10-year survival following resection for hepatocellular carcinoma. HPB (Oxford). 2012; 14: 285-290.
- 21, . Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. World J Gastroenterol. 2010; 16: 1436-1441.
- 22, , , et al. Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2008; 19: 862-869.
- 23, , , , . Arterial patency after repeated hepatic artery bland particle embolization. J Vasc Interv Radiol. 2010; 21: 522-526.
- 24, , , et al; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002; 359: 1734-1739.
- 25, , , et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002; 224: 47-54.
- 26, , , , . Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol. 2006; 17( 2 Pt 1): 217-223.
- 27, , , et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer. 2009; 115: 616-623.
- 28, , , et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol. 2012; 56: 1330-1335.
- 29, , , et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011; 140: 497-507.e2.
- 30, , , et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010; 138: 52-64.
- 31, , , et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol. 2011; 55: 1309-1316.
- 32, , , et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol. 2010; 12: 218-225.
- 33, , , et al. Stereotactic body radiation therapy for hepatocellular carcinoma. Discov Med. 2010; 9: 404-410.
- 34, , , et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2011; 81: e447-e453.
- 35, , , et al. Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma. Cancer. 2012; 118: 3191-3198.
- 36, , , et al. Radiofrequency ablation of hepatocellular carcinoma: long-term outcome and prognostic factors. Eur J Radiol. 2008; 67: 336-347.
- 37, , , et al. Comparison of survival rates after bland arterial embolization and ablation versus surgical resection for treating solitary hepatocellular carcinoma up to 7 cm. J Vasc Interv Radiol. 2005; 16: 955-961.
- 38, , , . Hepatocellular carcinoma: new options for image-guided ablation. J Hepatobiliary Pancreat Sci. 2010; 17: 399-403.
- 39, , , et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 2012; 107: 569-577; quiz 578.
- 40, , , et al. Long-term outcome of percutaneous ablation in very early-stage hepatocellular carcinoma. J Gastrointest Surg. 2011; 15: 2165-2171.
- 41, , , et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006; 24: 4293-4300.
- 42, , , et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378-390.
- 43, , , et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25-34.
- 44, , , , , . Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol. 2011; 29: 3960-3967.
- 45, , , et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer. 2011; 47: 2117-2127.